Q2 Q2 20 2018 18 Earn Earnings Presenta ings Presentation tion Aug ugust ust 7, , 20 2018 Paul R. Paul . Gudo Gudonis nis, , Chairman hairman and and C CEO EO Ralph alph Go Goldw ldwasser, asser, CFO FO Conq Conqueri ering g Up Uppe per r Limb Limb Para Paraly lysi sis s with with Wea Wearab rable e Me Medic dical al Robo Roboti tics cs 1
Legal Disclaimer This presentation contains forward-looking statements regarding the trading of the Company’s common stock on the NYSE American, the Company’s plans for the use of proceeds and advancing its product line, increasing its sales and marketing efforts and growing its business, and the Company's future business expectations, which are based upon the current estimates, assumptions and expectations of the Company’s management and its knowledge of the relevant market. The Company has tried, where possible, to identify such information and statements by using words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. Forward-looking statements, which are included in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, are only predictions and may differ materially from actual results due to a variety risks, uncertainties and other factors. These risks and uncertainties include, among others, risks related to the Company’s liquidity and financial position, the trading of its common stock, its new products, services, and technologies, government regulation and taxation, and fraud. More information about factors that potentially could affect Myomo's business and financial results are included in Myomo's Form S-1 Registration Statement filed with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events. 2
Scaling Up to Meet Large Unmet Need Addressable Market = Est. 25% of Upper Extremity Paralysis US: 3,000,000 Prevalence + 350,000 New Cases per Yr. + Worldwide Market 3
Investing in Revenue Growth with New Capital June 2017 4 Programs for Revenue Growth: U.S Sales & Marketing Product Development IPO + Private Placement = $7.9M Clinical Studies & Dec. 2017 Reimbursement Follow-on Offering = International Expansion $11.5M 4
Resulting in Record Revenue Q2 2018 700,000 +106% 600,000 500,000 400,000 +45% 300,000 200,000 100,000 0 1Q 2Q 3Q 4Q 2016 2017 2018 5
#1 Expanded US Distribution and Direct-to-Patient Marketing is Generating Demand Step 1 Step 2 Step 3 Open New Regions Expand Distribution Launch Digital Channel Marketing Campaign Hire Business Development Manager Recruit & Train O&P Host Patient Screening and Clinical Support Clinics Days 6
Step 1: Opening New Sales Regions Field Sales and Clinical Support 7
Step 2: Growing Roster of O&P Clinic Locations 8
Step 3: Launching Local Digital Marketing Activity 9
Screening Day Schedule 10
Growing # of Patient Screening Days Patient Pipeline Screening Days 80 70 60 50 40 30 20 10 0 Q1 Q2 Q3 11
#2: Product Development to Expand Market ADULTS (MyoPro2 JUNE 2017) ADOLESCENTS (JUNE 2018) PEDIATRICS (TBD) 12
Adolescent Launch Press Release Website Home Page and Landing Page Patient Champion Video Case Study Pilot Programs at Easterseals Chicago Shriner’s Chicago UCP Cleveland 13
Medicare Code Application – Status Dec 2017 May 2018 Fall 2018 Q1 2019 (Est) File HCPCS Preliminary Coverage Policy New Code, Code Decision to Determination; Policy, and Application Establish New Allowable Fee With CMS Code Reimbursement Go Live Amount Issued Note: There is no guarantee that CMS will follow through with code for MyoPro, coverage policy, or reimbursement amount 14
#4: Entering International Markets 15
Building European Distribution Network Attended OT World Conference in May 2018 Ottobock Has Fit Initial Patients in Germany Ottobock Will Be Exclusive MyoPro Distributor in Germany 16
European Target Countries Established Myomo Business Development Office in Europe Led by John Frijters, former Ottobock and ReWalk exec in Europe Recruiting Distributors in Selected Countries in Europe 17
New Hire: Micah Mitchell, Chief Commercial Officer Mission: Scale Revenue! “Front end of the business”: Field sales, Clinical Support, Channels, Marketing, Reimbursement, and Order Administration 20 years of experience in rapidly scaling companies in custom DME mobility solutions: - Invacare, Alliance Seating and Mobility, Apria Healthcare Group - Sales management, Payer contracts, Direct-to-consumer marketing 18
Revenue and Gross Margin - QTD QUARTER ENDED JUNE 30, 2018 2017 $ Change % Change REVENUE Product Revenue $ 627,887 $ 242,230 $ 385,657 159% Grant Revenue 4,482 64,453 (59,971) (93)% TOTAL $ 632,369 $ 306,683 $ 325,686 106% $ 431,923 $ 208,042 GROSS MARGIN 68% 68% 19
Revenue And Gross Margin - YTD SIX MONTHS ENDED JUNE 30, 2018 2017 $ Change % Change REVENUE Product Revenue $ 936,548 $ 440,023 $ 496,525 113% Grant Revenue 9,000 82,891 (73,891) (89)% 522,914 $ 422,634 TOTAL $ 945,548 81% GROSS MARGIN $ 637,022 $ 345,704 67% 66% 20
Gross Margin and Operating Expenses QUARTER ENDED JUNE 30, SIX MONTHS ENDED JUNE 30, 2018 2017 $ Change 2018 2017 $ Change Gross Margin $ 431,923 $ 208,042 $ 223,881 $ 637,022 $ 345,704 $ 291,318 Research and Development 486,982 708,622 (221,640) 859,341 1,065,507 (206,166) Selling, general and administrative 2,627,005 1,432,862 1,194,143 4,862,642 2,577,328 2,285,314 2,141,484 3,642,835 2,079,148 3,113,987 972,503 5,721,983 Loss from operations $(2,682,064) $(1,933,442) $ (748,622) $ (5,084,961) $ (3,297,131) $ (1,787,830) 21
Financial Position Jun. 30, 2018 Dec. 31, 2017 Cash $11.7M $12.9M Total Assets $13.1M $13.9M Debt $0.0M $0.0M $1.5M Total Liabilities $1.6M Stockholders' Equity $11.5M $12.4M Total Liabilities and Stockholders' Equity $13.1M $13.9M 22
Investor Summary: Catalysts for Growth #4: International Markets = More Population #3: Medicare Reimbursement Potential = Greater Patient Access # 2: New Product Development = More Target Patients #1: Increased US Distribution & Direct-to-Patient Marketing = More Demand MYO Current Base 23
Recommend
More recommend
